Synairgen plc: Synairgen to Present 60 and 90-day Long COVID

Analysis of 60 and 90-day data from Phase 3 SPRINTER trial in hospitalised COVID-19 patients showed that SNG001 reduced risk of recognised Long COVID symptoms Company to present full analysis

Related Keywords

Washington , United States , Namrata Taak , Geoff Nash , Mary Conway , Richard Marsden , Donna Davies , Duncan Monteith , Brooke Clarke , James Black , Mary Jane Elliott , Ratko Djukanovic , Freddie Barnfield , Chris Brightling , Lucy Featherstone , Numis Securities Limited Joint Broker , Head Of Communications , University Of Leicester , Drug Administration , Consilium Strategic Communications Financial Media , Patient Health , Department Of Respiratory Sciences , Mkc Strategies Llc Us Media Relations , University Of Southampton Professors Sir Stephen Holgate , Respiratory Sciences , United Kingdom Based , Fast Track , Southampton Professors Sir Stephen Holgate , General Anxiety Disorder , Functional Assessment , Chronic Illness Therapy , Fatigue Scale , Brief Pain Inventory , Short Form , Joint Broker , Charlie Beeson , Corporate Finance , Sunil De Silva , Securities Limited , Strategic Communications , Financial Media , Investor Relations , Jane Elliott , Synairgen , Present , Song , Covid , Data , Rom , Hase , Printer , Study , Hospitalised , Patients , Midweek , 022 ,